Superworth

Drugs Made In America Acquisition EPS DMAA

Diluted earnings per share by quarter and over the last twelve months, from 2024.

Last 12 months, to Jun 30, 2026
$0.21
Latest quarter, Q2 FY26
$0.06
−14% on a year earlier
Fiscal year 2025
$0.21

Drugs Made In America Acquisition's earnings per share was $0.21 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $0.06, down 14% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$0.21n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.06−14%$0.21
Q1 FY26$0.06+20%$0.22
Q4 FY25$0.02n/a$0.21
Q3 FY25$0.07n/an/a
Q2 FY25$0.07n/an/a
Q1 FY25$0.05n/an/a
Q3 FY24−$0.02n/an/a

Against its peers

Companies in Financial Services nearest Drugs Made In America Acquisition's size, closest first, today.

CompanyEPS, 12 monthsGrowth
DMAADrugs Made In America Acquisition$0.21
RMBIRichmond Mutual Bancorporation$1.21+29% a year
VABKVirginia National Bankshares$4.56+38% a year
NKSHNational Bankshares$3.18+80% a year
FXNCFirst National$2.40+140% a year
HWBKHawthorn Bancshares$3.67+24% a year
EFSIEagle Financial Services$3.46+60% a year
FNRNFirst Northern Community Bancorp$1.35+13% a year
GBFHGBank Financial$1.28−7% a year
WNEBWestern New England Bancorp$0.84+42% a year
SNFCASecurity National Financial$1.44+40% a year
Peer median$1.92

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Drugs Made In America Acquisition

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.